Announcements Trials
Browse Landscape

Phase

Phase 3 100Phase 2 89Phase 1 56Phase 1/2 34Phase 4 7Phase 2/3 7Phase NA 2Phase EARLY_PHASE1 2

Status

Unknown 1Terminated 1

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Breast Neoplasms 1

Interventions

fludarabine 9Cyclophosphamide 9pembrolizumab 5Oncolytic Virotherapy 4Nivolumab 4Cholestanetriol 26-Monooxygenase 3atezolizumab 2alpha-Synuclein 2Trastuzumab 2Influenza Vaccines 2Blood Specimen Collection 2Ascorbic Acid 2tinostamustine 1sugemalimab 1spartalizumab 1ruxolitinib 1reolysin 1pexidartinib 1methyl prednisolonate 1irinotecan sucrosofate 1fiu protein, E coli 1camrelizumab 1avelumab 1apatinib 1VTX-2337 1Temozolomide 1TAK-981 1Sorafenib 1Radiation 1RXDX-106 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × INDUSTRY × Trastuzumab × Clear all
NCT06098898 2023-10-25

Safety and Efficacy of NK510 to Treat Gastric Cancer

Base Therapeutics (Shanghai) Co., Ltd.

Phase EARLY_PHASE1 Unknown
9 enrolled
Gastrointestinal

Stomach Neoplasms

NCT04102618 2022-08-15

AWARE-1

Oncolytics Biotech

Phase EARLY_PHASE1 Terminated
26 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡